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Endovascular therapy for infected aortic
aneurysms
Boonprasit Kritpracha, MD, Dhanakom Premprabha, MD, Jitpreedee Sungsiri, MD,
Wittawat Tantarattanapong, MD, Sorracha Rookkapan, MD, and Pong Juntarapatin, MD, Hat Yai,
Songkhla, Thailand
Objective: To determine the outcome of endovascular therapy for an infected aortic aneurysm in patients with or without
aorto-aerodigestive/aortocaval fistulas.
Methods: From September 2005 toMay 2010, 21 patients, 17 abdominal and four thoracic infected aortic aneurysms were
treated with an endovascular stent graft at Songklanagarind Hospital, Thailand. Five patients presented with fistula
complications, 1 aortoesophageal, 1 aortobronchial, 1 aortocaval, and 2 aortoenteric fistulas. Lifelong antibiotics were
planned for all patients. In-hospital mortality and follow-up outcomes were examined.
Results: The average age was 66 years (range, 42-84) and 18 patients were male. All five cases in the fistulous group
presented with symptoms related to the organs involved, four massive bleedings and one congestive heart failure.
Symptoms of patients in the nonfistulous group were abdominal, back, or chest pain in 94%, fever in 81%, and diarrhea
in 19%. Blood culture was positive in 10 patients (48%): eight Salmonella spp and two Burkholderia pseudomallei. The
overall in-hospital mortality was 19% (4/21): 60% (3/5) in the fistula group and only 6% (1/16) in the nonfistula group.
One conversion to open repair was performed in the fistula group 2 weeks after the endovascular procedure. During the
follow-up period, one of the two survivors in the fistula group died at 18 months from unrelated causes, while there were
no deaths in the 15 patients of the nonfistula group with an average patient follow-up of 22 months (range, 1-54).
Periaortic inflammation and aneurysms in the nonfistula group completely disappeared in 10 of the 15 patients (67%).
The aneurysm significantly shrunk in four patients (27%), and was stable at 1 month in one patient. There were no late
conversions.
Conclusion: Endovascular therapy, as a definite treatment for infected aortic aneurysms, provided excellent short- and
medium-term results in patients without fistula complications. However, a poorer outcome was evident in patients with
fistula complications. ( J Vasc Surg 2011;54:1259-65.)
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GAn infected aortic aneurysm is rare and considered to
be one of the most challenging problems faced by vascular
surgeons. The standard treatment of performing an open
repair with a resection of the infected aortic segment,
extensive debridement of the surrounding tissue, and in
situ or extra-anatomic bypass carries a significant morbidity
and mortality rate. Operative mortality has been reported
to be as high as 44%.1-4
Endovascular aneurysm repair (EVAR), a less invasive
option for patients with this serious condition, was first
reported by Semba et al.5 Over the past decade, there have
been many reports of successful EVAR for infected aortic
aneurysms, even though some patients experienced an un-
favorable outcome.6-14 Most of the reports had a small
number of patients with a short-term follow-up. Contro-
versy continues over the role of EVAR, whether it should
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doi:10.1016/j.jvs.2011.03.301e considered as a definite treatment or more of a “bridge-
rocedure” to improve a patient’s condition awaiting open
epair.15
In the past several years in our hospital, EVAR has been
ur preferred choice of treatment in patients with infected
ortic aneurysm since these patients are considered to be
igh risk for open repair. In this study, we review our
xperience of EVAR in infected aortic aneurysms with or
ithout fistula complications and assess its efficacy and
urability.
ETHODS
From September 2005 to May 2010, 21 consecutive
atients with infected thoracic or abdominal aortic an-
urysms (TAA or AAA) were treated with an endovascu-
ar stent graft at our institution, Songklanagarind Hos-
ital in southern Thailand (17 abdominal and 4 thoracic
nfected aortas). Infected aortic aneurysms were diag-
osed and categorized into two groups based on the
ollowing criteria:
roup I – Fistulous group: Patients who presented with
clinical evidence of fistulous complications of an aortic
aneurysm, including aortoenteric, aortobronchial, aor-
toesophageal, and aortocaval fistulas.
roup II –Non-fistulous group: Patients who presented with
clinical evidence of bacterial aortitis or infected aortic
aneurysm (fever, abdominal/back, or chest pain), with-
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November 20111260 Kritpracha et alout fistulous complications. In cases with negative blood
culture, in addition to the clinical symptoms of fever and
pain, the diagnosis required evidence of a typical imaging
appearance of infected aneurysm, including periaortic in-
flammation, saccular aneurysm, and/or leakage.
Preoperative imaging studies, device selection, and op-
erative procedures were conducted using the same princi-
ples as are applied to our regular endovascular aortic ther-
apy practice. All aortic stent graft procedures were
performed in the operating room with thoracic cases under
general anesthesia and abdominal cases under local anes-
thesia. The devices used were oversized by 15% to 20% of
the native vessel diameter.
Antibiotics were prescribed according to the sensitivity
obtained from the blood cultures. In cases with a negative
blood culture, antibiotics were prescribed to cover salmo-
nella, the most common pathogen causing bacterial aortitis
in the region. Parenteral antibiotics were administered for
at least 10 days, until the patient was afebrile for 72 hours.
Technical success was defined as successful at stopping
the bleeding in the patients in group I, and successful
exclusion of an aneurysm or leakage from circulation with-
out endoleak in the patients in group II.
After the first 30-day visit, patients were followed up
every 3 months during the first year and every 6 months
thereafter. Follow-up imaging studies by computed to-
mography (CT) scan were performed at 1, 6, and 12
months, and yearly thereafter. Lifelong antibiotics were
planned for all patients.
The demographic data, causative bacteriology, devices
used, perioperative outcomes, and follow-up data were
Table. Medical comorbidities, clinical presentations, and o
aneurysm patients
Pt Sex, age Diagnosis Associated disease
F1 M, 79 Aortobronchial fistula HTN
F2 M, 50 Aortocaval fistula DM, CKD
F3 M, 60 Aortoenteric fistula DM
F4 M, 62 Aortoenteric fistula COPD
F5 F, 84 Aortoesophageal fistula CKD, CAD
N1 M, 63 Infected AAA DM, CKD, stroke
N2 M, 79 Infected TAA HTN
N3 F, 79 Infected AAA DM
N4 M, 42 Infected AAA HIV
N5 M, 59 Infected AAA —
N6 M, 67 Infected AAA HTN
N7 M, 48 Infected AAA HIV
N8 M, 68 Infected AAA HTN, asthma
N9 M, 65 Infected AAA HTN
N10 M, 81 Infected AAA DM, HTN
N11 M, 58 Infected AAA DM, HTN
N12 M, 70 Infected AAA CAD
N13 M, 58 Infected AAA DM, HTN, CKD
N14 F, 74 Infected AAA HTN
N15 M, 63 Infected TAA DM
N16 M, 73 Infected AAA DM
AAA, Abdominal aortic aneurysm; AUI, aortouniiliac device; CAD, coro
pulmonary disease; DM, diabetes mellitus; HIV, human immunodeficiencystudied. (ESULTS
There were 18 males and three females with an average
ge of 66 years (range, 42-84 years) enrolled in the study.
wo patients with HIV infection had their diseases at a
ounger age than the average, 42- and 48-years-old. Six-
een patients presented with clinical symptoms of microbial
ortitis or infected preexisting aortic aneurysm without
stula, while five presented with fistula complications: one
ortoesophageal, one aortobronchial, one aortocaval, and
wo aortoenteric fistulas.
Patient comorbidities are shown in the Table. There
as no difference in comorbidities between the groups.
he prevalence of diabetes mellitus was quite high, at
0% and 44% in the fistulous and nonfistulous groups,
espectively.
As shown in the Table, the clinical presentations of the
atients with fistulous complications were specific to the
rgan involved. The first case (F1) was a 79-year-old male
ith an 8-cm thoracic aortic aneurysm who presented with
emoptysis. The second case (F2) was a 50-year-old male
ho had developed congestive heart failure from an aorto-
aval fistula after he had been treated for salmonella septic
rthritis for 8 weeks. Another three cases presented with
assive gastrointestinal bleeding and hypotension (defined
s systolic blood pressure 80 mm Hg). Preoperative
emoglobin readings of these three cases (F3-5) were 8.1
%, 7.1 g%, and 8.5 g%.
For patients in the nonfistulous group, 81% (13/16)
ad fever, 94% (15/16) had abdominal, back, or chest pain,
nd 19% (3/16) had diarrhea. Leukocytosis (defined as
hite blood cell count 10  109/L) was found in 80%
mes of the fistulous and nonfistulous infected aortic
cal presentation WBC (109/L) Pre-op images Prior ATBs
optysis 9.2 L
r, CHF 17.1 L Yes
leeding 18.8 I, L
r, GI bleeding 14.9 I, L
leeding 12.6 I, L
fever 13.0 I, L Yes
r 7.6 I, L
fever 13.8 I, L Yes
diarrhea 11.9 I, L
fever 13.1 I
fever 22.6 I, L
fever 4.5 I, L Yes
diarrhea 9.6
fever 14.6 I Yes
13.4 I, L
fever 11.2 I, L Yes
fever 7.5 I
fever 11.9 I, L
fever 11.8 I, L Yes
fever 13.0 I, L Yes
fever, diarrhea 11.1 I, L Yes
artery disease; CKD, chronic kidney disease; COPD, chronic obstructive
HTN, hypertension; I, periaortic inflammation; L, aortic leakage.utco
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Volume 54, Number 5 Kritpracha et al 1261groups, respectively. Preoperative hypotension was found
in only one patient (N1) in the nonfistulous group, the one
who had severe sepsis. The postoperative course did not
improve in this patient, and the family did not wish to have
open surgery. This was the only patient who expired from
the disease in group II.
Nine patients received antibiotics prior to their referral
to our hospital. Two of the nine had been treated for
established infections of other organs prior to the develop-
ment of the infected aorta. Patient F2, a 50-year-old man,
was treated for salmonella sepsis for almost 2months before
he developed symptoms of congestive heart failure from
aortocaval fistula. Patient N15, a 63-year-old man, devel-
oped an infection of the thoracic aorta 6 weeks after being
treated for septic arthritis of his right knee. Blood culture
revealed the same organism as the culture taken from the
fluid from his knee, Burkholderia pseudomallei. The other
seven patients had received antibiotics prior to their referral
to our hospital.
Almost every patient, 20 out of 21, had abnormal
imaging studies. Leakage was evident in all five cases with
fistulous complications. Periaortic inflammation, saccular
aneurysm, or leakage was found in all but one case in the
nonfistulous group. The exception was patient N8, a 68-
year-old man with a 6.2-cm AAA who had been treated for
diarrhea for 10 days before presenting with acute tender-
ness of the aneurysm, and blood culture was positive for
salmonella. This was the only patient in this series that CT
scan showed no periaortic inflammation or leakage.
Of all 21 patients, 10 (48%) had positive blood cul-
tures. Salmonella was the most common pathogen found,
Table. Continued.
Culture Devices used Antibiotics used
F/U
(months)
No growth Thoracic Cefspan 18 S
Salmonella Bifurcated Cotrimoxazole 37
Salmonella Bifurcated — —
No growth AUI — —
No growth Thoracic — —
Salmonella Bifurcated Ciprofloxacin —
Salmonella Thoracic Ciprofloxacin 1 S
No growth Aortic cuff Ciprofloxacin 10 D
Salmonella AUI Cotrimoxazole 11 D
Salmonella Bifurcated Ciprofloxacin 12 S
No growth Bifurcated Ciprofloxacin 16 D
No growth Bifurcated Cotrimoxazole 17 D
Salmonella Bifurcated Ciprofloxacin 18 S
No growth AUI Ciprofloxacin 20 S
No growth Bifurcated Ciprofloxacin 23 D
Salmonella Bifurcated Ciprofloxacin 24 D
No growth Bifurcated Ciprofloxacin 26 S
No growth Iliac device Ciprofloxacin 26 D
B pseudomallei AUI Augmentin 30 D
B pseudomallei Thoracic Augmentin 36 D
No growth Bifurcated Ciprofloxacin 54 Din eight of the 10. Burkholderia pseudomallei, melioidosis, was found to be the causative organism in the other two
atients.
Perioperative outcomes. A number of different types
f devices were used in the 17 abdominal cases: 11 cases
sed bifurcated device, 4 cases used aortouniiliac device, 1
ase with a small aorta used an iliac limb device, and 1 case
ith a short diseased aortic segment used an aortic exten-
ion cuff. Of the four thoracic cases, hybrid procedure was
erformed in one case. A combined carotid-carotid and
arotid-left subclavian bypass was performed in an 84-year-
ld woman with a 9.4 cm TAA who presented with massive
ematemesis from an aortoesophageal fistula. All endovas-
ular stent grafts were deployed successfully. There were no
erioperative complications relating to the endovascular
rocedures.
Technical success was achieved in all 21 patients. Bleed-
ng stopped immediately after the stent graft deployment in
ll five patients of the fistulous group. However, rebleeding
ccurred in two patients. Patient F3, a 60-year-old man
ho originally presented with massive bleeding from an
ortoenteric fistula had rebleeding the day following the
rocedure, while the aortoesophageal fistula patient, F5,
ho had the hybrid procedure suffered from rebleeding 2
eeks after the procedure.
Fever at presentation was found in only 40% (2/5) of
he fistula patients (F2 and F4, Table). Patient F2, an
ortocaval fistula, also continued to have fever despite the
verall improvement of his congestive heart failure symp-
oms. Explantation of the stent graft and axillobifemoral
ypass graft was performed at 4 weeks poststent graft.
nother patient, F4, despite responding well to the EVAR,
ow-up aneurysm size
Expired (stroke, 18 months PO)
— Explanted, open repair (at 4 weeks PO)
— Expired (rebleeding, 1 day PO)
— Expired (sepsis, 63 days PO)
— Expired (rebleeding, 13 days PO)
— Expired (sepsis, 9 days PO)
eared since 6 months
eared since 1 year
15 mm
eared since 6 months Thrombosed limb
eared since 1 year Thrombosed limb
15 mm
14 mm
eared since 1 year
eared since 1 year
10 mm
eared since 6 months
eared since 1 year
eared since 1 year
eared since 6 monthsFoll
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from multiple organ failure 2 months postoperation (Fig
1). In contrast, 81% (13/16) of the nonfistula patients
presented with fever, and all but one case responded well to
the treatment, with the fever disappearing within 5 days.
The only nonimproved patient, N1, had severe sepsis and
expired 9 days postimplantation.
The overall in-hospital mortality was 19% (4/21), only
6% (1/16) in the nonfistulous group, but 60% (3/5) in the
fistulous group, P  .008 (2 test). Re-operation was
performed in one case, patient F2 (an open repair 4 weeks
after the initial endovascular procedure for the aortocaval
fistula). Stent graft explantation and aortic exclusion with
an axillobifemoral bypass graft was performed. There were
no secondary endovascular procedures needed in the other
cases. The average hospital stay was 25 days (range, 10-70
days) among the surviving cases.
Follow-up outcome. The average follow-up period
was 22 months (range, 1-54 months). One of the two
patients who survived after the treatment in the fistulous
group died at 18 months from nonaortic aneurysm-related
causes. The only survivor from the fistulous group at the
time of this report was the aortocaval fistula case who had
received a subsequent open repair 4 weeks after the initial
stent graft procedure. There were no deaths among the 15
survivors in the nonfistulous group.
No cases required conversion or a secondary procedure
during the follow-up period. Fourteen out of 15 patients in
the nonfistulous group had significantly decreased periaor-
tic inflammation and aneurysm size at 6-month follow-up
and beyond, as shown in the Table. Complete resolution of
the periaortic inflammatory tissue and aortic aneurysm was
seen in 10 patients; at 6 months in 4 cases, and at 12
months in the other 6 cases. A significant decrease in the
aortic aneurysm diameter (5 mm) was seen in four of the
remaining patients, while the last patient, who only had a
1-month follow-up, had no significant change in the
aortic aneurysm morphology at that follow-up. The lon-
gest follow-up was 54 months in a 73-year-old man,
whose infected aorta became normal 6 months after the
EVAR (Fig 2) and was still normal at the final follow-up.
There were no cases of postoperative endoleak. Iliac
Fig 1. A serial of abdominal computed tomography (
bleeding from aortoenteric fistula, demonstrated a signifi
1 month despite a large fistulous connection.limb thrombosis occurred in two cases. Buttock claudi- lation symptoms in these patients improved without
ntervention.
ISCUSSION
Infected aortic aneurysm is rare and its initial symptoms
re subtle and nonspecific.16 However, the classical triad of
eatures of fever, abdominal/back or chest pain, and leuko-
ytosis are present in the majority of cases.1,10 Periaortic
oft tissue inflammation and/or aortic leakage are typical
ndings in CT scans.16 In our series, almost all cases
resented with typical features of infected aortic aneurysm
nd changes in imaging studies. Because of nonspecific
ymptoms in the early phase of the disease, almost half of
ur patients received antibiotic treatment prior to a definite
iagnosis being made.
Salmonella and Staphylococcus aureus are the two most
ommon causative organisms of infected aortic aneurysm
eported in themedical literature,3,6,7,10,12,14 with S aureus
he main reported causative pathogen for an infected aortic
neurysm in western countries3,6,10,12 and Salmonella the
ajor reported causative agent in Asia.11,14
In our series, Salmonella was the predominant patho-
en, together with, interestingly, melioidosis infection in
wo cases. Melioidosis, a disease caused by Burkholderia
seudomallei, is regarded as endemic to southeast Asia and
orthern Australia, with sporadic case reports from other
egions such as central and southern America, the Carib-
ean, and Africa.17,18 Diabetes, thalassemia, renal disease,
nd occupational exposure to surface water such as rice
armers have been associated with an increased risk for
elioidosis.19 The most common presentation of melioid-
sis is pneumonia, in approximately half of all cases, with
ther common presentations, including genitourinary in-
ections, skin and soft tissue infections, splenic/liver and
rostatic abscesses, and bone and joint infections.18 In-
ected aortic aneurysm due to melioidosis is rare, with high
orbidity and mortality.20
One of the most challenging issues for vascular sur-
eons is a serious presentation of infected aorta associated
ith a fistulous connection with an adjacent organ such as
he gastrointestinal tract or lower respiratory tract causing
assive bleeding. Fistulas can arise from the erosion of a
scan studies in a patient who presented with massive
shrinkage of abdominal aortic aneurysms (AAA) withinCT)
cantarge atherosclerotic aortic aneurysm, a rupture of a pseu-
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tions following open AAA repair. The clinical status of the
fistula patients in our study was generally more debilitated
than the nonfistula group because of the combined insults
from sepsis and massive bleeding. Prognosis of our patients
with an infected aortic aneurysm complicated with a fistula
was poor. The causes of death were aneurysm-related in the
early postoperative phase and from associated comorbidi-
ties during later follow-up. The comparisons of mortality
rates between the fistulous vs the nonfistulous groups were
60% (3/5) vs 6% (1/16) perioperatively, and 50% (1/2) vs
0% (0/15) during the follow-up. Our observations suggest
that EVAR may not be able to control massive bleeding in
all patients with aortoenteric fistula.
Open repair is the established treatment for an infected
aortic aneurysm, consisting of aneurysm resection, exten-
sive local debridement, and revascularization.1-4 To avoid
placing vascular graft in a contaminated area, an extra-
anatomic bypass has been advocated. However, significant
complications can occur with such a bypass, most notably
poor long-term patency of the axillobifemoral bypass grafts
or bleeding from the aortic stump. In situ graft repair has
been reported to be a feasible technique in cases where
there is an absence of grossly local infection or pus.3,4
Morbidity and mortality following open repair has been
reported to be as high as 44%.2 Unfavorable outcomes
generally result from performing major aortic surgery in
patients already debilitated from sepsis and/or massive
bleeding together with having significant comorbidities.
EVAR for infected aortic aneurysm treatment was first
reported over a decade ago.5 The main advantages of
endovascular repair are the avoidance of a large incision,
aortic cross clamping, interference with respiratory func-
Fig 2. Complete shrinkage of periaortic inflammatition, revascularization, and significant blood loss.5,6 Since bts introduction there have been a number of small case
eries reports showing good results.7-12 A systemic review
ound 48 cases of infected aortic aneurysms treated by
VAR from 22 reports.6 The overall 30-day mortality rate
rom all of these studies due to massive bleeding or sepsis
as 10.4%, and the study concluded that patients with an
neurysm rupture and fever at the time of the operation had
poor prognosis. However, in our study, fever and aneu-
ysm leakage were found in almost every case of the “non-
stula” group, yet a good outcome was achieved in all but
ne case. The only nonresponsive case in this group con-
inued to have a high fever postoperatively. A poor prog-
osis, according to our study, was primarily found in pa-
ients in the late stage of disease who presented with
stulous connections with adjacent organs or severe sepsis
nd who failed to improve after treatment with EVAR and
arenteral antibiotics.
There have also been several reports of unfavorable
utcomes from the use of an endovascular stent graft in
nfected aortic aneurysm repairs.7,15,21-23 Unsuccessful at-
empts to control bleeding by EVAR in aortoenteric fistulas
ave also been experienced. We consider that our results to
ate with using EVAR in treating patients with fistulous
omplications are not satisfactory. EVAR can serve as a
ridging procedure to temporarily stop the bleeding, but
pen repair is the definitive treatment to prevent recurrent
leeding, if the patient’s status allows.
Late failure due to reinfection has also been re-
orted.15,16,21,22 Implantation of a foreign body, a stent
raft, into an infected field is a concern with EVAR
reatment in infected aortic aneurysms. However, in our
ases, the inflammatory tissue around the aorta re-
ponded extremely well to a treatment of EVAR com-
to 4-year follow-up in a 63-year-old male patient.ined with antibiotics.
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shrinkage or complete disappearance by their 12-month
follow-up, and they continued to do well during the
longer follow-up without any recurrent infection. The
longest follow-up was 54 months, the average 22
months. In this relatively “earlier” stage of the disease,
nonfistula, aggressive debridement of the infected tissue
may not be needed. As noted by Patel et al, antibiotic
therapy may be able to sterilize the native aorta, while the
same results may not be achieved in cases with infected graft
material.8
Infected aortic aneurysms occurred at a younger age in
our two HIV-infected patients in this series, but similar
outcomes were achieved in both cases with the endovascu-
lar technique. All inflammatory tissues in both HIV-
infected patients disappeared within 1 year. EVAR seems to
be a suitable treatment modality for this group of patients
because of the benefits of minimal blood loss, decreasing
the chance for contamination, with a good outcome.
There was no second endovascular procedure required
in any of our cases, although two iliac limb occlusions
occurred. Both cases presented with leakage of the small
aortas, and bifurcated devices were chosen due to aorto-
uniiliac (AUI) devices not being available at the time of the
operations. Because of their health status, buttock claudi-
cation symptoms did not interfere with their daily activities.
There were no other serious pelvic ischemic complications.
The buttock claudication symptoms improved within 6
months in both cases.
Patient compliance with lifelong antibiotics is critical to
achieving a good outcome. All of our patients complied
with the treatment protocol, and no patients had been lost
to follow-up as of this writing. Cessation of oral antibiotics
may cause reinfection or stent graft infection, although the
necessity of lifelong antibiotics in cases of this nature is still
debated.6
CONCLUSION
Our study shows that EVAR is an effective treatment
for uncomplicated infected aorta without fistulous connec-
tion. Immediate improvement in abdominal or back pain
followed by fever disappearance within 4 to 5 days indicates
a good treatment result. CT scan reveals significant shrink-
age of aneurysm and periaortic inflammatory tissue in as
early as 2 weeks postoperatively. Our current plan for
patients with this condition is lifelong antibiotics after
EVAR. In patients with a fistulous connection, the results
were not as good as with the uncomplicated group, but
EVAR was still an effective option for the initial treatment
to close the fistula. However, rebleeding did occur, thus
close follow-up should be maintained in such cases, and
open repair may be needed in cases in which EVAR is
deemed to have failed. The presentation of fistulous con-
nections with adjacent organs or severe sepsis which fails to
improve after EVAR signifies a poor prognosis in patients
with an infected aortic aneurysm.UTHOR CONTRIBUTIONS
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Dr Ronald Fairman (Philadelphia, Pa). The obvious ques-
tion for the nonfistula group is your management of antibiotics. Is
it for life?
Dr Kritpracha. All of our patients received lifelong anti-
biotics.
Dr Fairman. We have also been taught in this country that
salmonella can be one of themost virulent organisms to involve the
arteries. You give a more optimistic view of that. Can you com-
ment?
Dr Kritpracha. Most of the reported series in the literature
are mixed cases, consisting of cases with and without fistulous
connections together with different pathogens. It is difficult to
conclude which group of infected aortic aneurysm patients will
respond well to particular type of therapy. We believe that there are
stages of the disease, not all infected aortic aneurysms are the same.
Infected aneurysm with fistulous connection generally is a more
advanced disease. When we look at the treatment results, we
uniformly achieved good results when treated nonfistula infected
aortic aneurysm cases with endovascular technique, while the
treatment of cases with fistulous connections was still challenging.
Even though most of bacteria found in our study were salmonella,
with a few cases of melioidosis, they seem to respond well to EVAR
in the condition of no fistulous connections.
Dr Linda Harris (Buffalo, NY). My question is about the
fistula group. We have treated a number of these patients as a
hybrid procedure where we have repaired the aorta with a stent
graft, but then gone in and repaired the bowel separately. It
seemed from your presentation that you are treating them only
with a stent graft and not doing anything to repair the bowel. Can
you clarify whether you repair the bowel or just treat with a stent
graft.
Dr Kritpracha. In this series, we did not attempt to close the
gastrointestinal defect after stent graft procedure. We had mixed
results. There was a patient that I showed in the figure, had
aortoenteric fistula presenting with massive GI bleeding. Bleeding
stopped immediately after deploying the stent graft. CT scan thellow us to perform any major surgery. The follow-up CT scan in
-week time showed significant shrinkage of the aneurysm. Unfor-
unately, this patient died from severe pneumonia. A lesson learned
rom this case was that a large defect could be resolved, but we
annot assume it will be true for every case. On the contrary, we
ost two patients from recurrent bleeding, one aortoenteric fistula
nd one aortoesophageal fistula. I believe that there is a certain role
or closing GI defect if we are able to do so.
Dr William Tanski (Concord, NH). Which aortic endografts
id you use? Different endografts may have different rates of
esidual or recurrent infection.
Dr Kritpracha. The question is the endograft that were being
sed in this study, right?
Dr Tanski. Yes.
Dr Kritpracha. All of the devices we used were stent grafts
ith Dacron fabric. We did not yet use stent grafts with PTFE
abric. Our study cannot provide the answer whether the Dacron
abric is superior or inferior to PTFE fabric when deployed in
nfected fields.
Dr Joseph Mills (Tucson, Ariz). Number one, could you talk
little bit more about what the organisms were, and did you
orrelate good or poor outcome with the type of organism?
The second question is timing. If you have a patient that
resents with aortic infection but their hemodynamics are stable
nd they are not ruptured, do you try to culture and treat the
rganism first for a period of time before you put the stent graft in?
Dr Kritpracha. For the first question, the majority of bacteria
e found were salmonella. Only two cases were infected with
urkholderia pseudomallei and one with Klebsiella pneumoniae. I
hink we do not have enough subjects to compare which one is
ore virulent. But at least we know that in salmonella infection and
elioidosis, treatment with EVAR is quite acceptable. For the
iming of the procedure, we had some poor outcome of medical
reatment for infected aortic aneurysm. In the past, we had a few
ases that aneurysm grew significantly despite receiving parenteral
ntibiotics. It is our practice to offer EVAR once the diagnosis of
nfected aortic aneurysm has been made.
